Cullinan Therapeutics, Inc.
CGEM · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $83 | $98 | $156 | $60 |
| Short-Term Investments | $316 | $369 | $311 | $231 |
| Receivables | $3 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $13 | $13 | $7 | $6 |
| Total Curr. Assets | $415 | $480 | $474 | $297 |
| Property Plant & Equip (Net) | $2 | $4 | $5 | $0 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $204 | $0 | $81 | $140 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $0 | $0 | $0 | $0 |
| Total NC Assets | $207 | $4 | $87 | $141 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $622 | $484 | $561 | $437 |
| Liabilities | – | – | – | – |
| Payables | $2 | $2 | $3 | $3 |
| Short-Term Debt | $1 | $1 | $2 | $0 |
| Tax Payable | $0 | $0 | $4 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $28 | $24 | $14 | $9 |
| Total Curr. Liab. | $31 | $28 | $22 | $12 |
| LT Debt | $1 | $2 | $4 | $0 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $0 |
| Total NC Liab. | $1 | $2 | $4 | $0 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $2 | $4 | $5 | $0 |
| Total Liabilities | $31 | $30 | $26 | $12 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$368 | -$201 | -$48 | -$159 |
| AOCI | -$0 | -$0 | -$3 | -$1 |
| Other Equity | $959 | $655 | $585 | $585 |
| Total Equity | $590 | $454 | $535 | $425 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $622 | $484 | $561 | $437 |
| Net Debt | -$81 | -$95 | -$151 | -$60 |